Poland· PL-100247163

Reparil Gel N

A medicinal product containing escinum + diethylamini salicylas, registered in Poland by Cooper Consumer Health B.V..

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedReparil Gel NATC—REGISTER NO.PL-100247163PACKS LISTED2CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Escinum + Diethylamini salicylas
Manufacturer
Cooper Consumer Health B.V.
Country
Poland (PL)
ATC code
—
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990116621
  • gtin
    05909990116614

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ae348126-ac85-4454-839f-e02b5cf6faa8
GET /v1/drugs/ae348126-ac85-4454-839f-e02b5cf6faa8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Żel",
  "source": "urpl",
  "strength": "(10 mg + 50 mg)/g",
  "packaging": "05909990116621 ¦ OTC ¦ 8634\n1 tuba 100 g\n05909990116614 ¦ OTC ¦ 50369\n1 tuba 40 g",
  "substance": "Beta Aescinum 1 g/100 g + Diethylamini salicylas 5 g/100 g",
  "common_name": "Escinum + Diethylamini salicylas",
  "pl_product_id": "100247163",
  "pozwolenie_nr": "01166",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about escinum + diethylamini salicylas.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.